Hong Kong: New Horizon Health plans HK IPO

The pipeline of mainland companies wanting to list in Hong Kong shows no sign of slowing down with cancer diagnostics company New Horizon Health just the latest to file to the HKEx. The pioneer in China’s colorectal cancer screening market, the company’s ColoClear proprietary, non-invasive, multi-target, FIT-DNA test, is the first and only molecular cancer…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »